ATR vs SLGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: SLGN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ATR and SLGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ATR and SLGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AptarGroup makes the precision dispensing and drug-delivery systems that sit on top of everyday products: nasal spray and inhaler valves for pharma, pumps and airless systems for fragrance and skincare, and dispensing and non-dispensing closures for food, beverage, personal care, and home care. The company runs three reporting segments (Pharma, Beauty, and Closures), with Pharma generating the bulk of profit thanks to long-cycle, regulated, high-margin drug-delivery contracts. Aptar serves a global customer base and positions itself around active material science and delivery precision rather than commodity packaging.

Full ATR guide

Silgan Holdings Inc. is a leading maker of sustainable rigid packaging for essential consumer goods, operating in three segments: Dispensing and Specialty Closures (pumps, sprayers, triggers, and caps for fragrance, beauty, healthcare, food, and beverage), Metal Containers (steel and aluminum cans for food and pet food), and Custom Containers (custom-designed plastic containers). Metal Containers has historically been about half of sales while Dispensing and Specialty Closures has grown, boosted by acquisitions, to roughly 45% of revenue, giving Silgan a mix of a stable, high-share North American food-can franchise plus a higher-value dispensing business. Because its customers are consumer-staples companies, demand is relatively steady across economic cycles, and most cost inflation (steel, aluminum, resin) is passed through to customers under contract, though often on a lag.

Full SLGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ATR drivers: High-margin pharma drug delivery; Beauty and consumer recovery.
• SLGN drivers: Dispensing and specialty closures mix shift; Defensive staples demand and cost pass-through.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Core organic sales have been roughly flat, so headline growth has leaned on acquisitions and currency, which is lower-quality growth. For SLGN, the main risk is slow organic growth: Silgan is a mature, capital-intensive packaging supplier, so volume gains are modest and much of the growth story depends on acquisitions and mix shift rather than end-market expansion.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ATR if you believe its drivers more; SLGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ATR and SLGN guides.

ATR. Aptar trades like a quality defensive industrial: a mid-20s earnings multiple, a low beta near 0.4, and a 30-plus year dividend-growth record. The key valuation tension is paying a premium multiple for a business whose organic sales are currently near flat, so the case depends on pharma mix, margin recovery, and eventual beauty and closures reacceleration.

SLGN. Figures are approximate and tied to the asOf date; verify live numbers before acting. Silgan trades at a mid-teens trailing and low-teens forward earnings multiple, roughly in line with slow-growth industrial packaging peers, reflecting steady but modest growth rather than a premium franchise. Free cash flow of about ~$450 million and net leverage near ~3.5x EBITDA mean the valuation case leans as much on cash generation, dividend growth, and deleveraging as on earnings expansion.

Headline figures (approximate, July 2026): ATR shows revenue (ttm) ~$3.9B, q1 2026 sales ~$983M (+11% reported, ~flat core), q1 2026 adjusted eps ~$1.19, market cap ~$8.6B; SLGN shows revenue (2025) ~$6.48 billion (Q1 2026 was ~$1.56 billion, up ~6% year over year), adjusted eps (q1 2026) ~$0.78 (down from ~$0.82 a year earlier), full-year 2026 eps guidance ~$3.73 to ~$3.93 (adjusted), market cap ~$4.2 to ~$5 billion (stock ~$40 per share).

ATR and SLGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ATR and SLGN exposure against your real portfolio. It is not an investment adviser.